Oncologix Tech Inc
Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. It offers personal home care services, including daily living assistance, companionship, and homemaker services, as well as Alzheimer's care, home care resource planning, and medical care coordination services. The company also manufactures, markets, and distributes medical technologie… Read more
Oncologix Tech Inc (OCLG) - Total Assets
Latest total assets as of November 2022: $4.85K USD
Based on the latest financial reports, Oncologix Tech Inc (OCLG) holds total assets worth $4.85K USD as of November 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oncologix Tech Inc - Total Assets Trend (1996–2017)
This chart illustrates how Oncologix Tech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oncologix Tech Inc - Asset Composition Analysis
Current Asset Composition (August 2017)
Oncologix Tech Inc's total assets of $4.85K consist of 16.7% current assets and 83.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.1% |
| Accounts Receivable | $209.58K | 14.0% |
| Inventory | $3.00K | 0.2% |
| Property, Plant & Equipment | $13.87K | 0.9% |
| Intangible Assets | $1.20 Million | 80.0% |
| Goodwill | $1.19 Million | 79.6% |
Asset Composition Trend (1996–2017)
This chart illustrates how Oncologix Tech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncologix Tech Inc's current assets represent 16.7% of total assets in 2017, a decrease from 30.2% in 1996.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2017, down from 18.7% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 159.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is intangible assets at 80.0% of total assets.
Oncologix Tech Inc Competitors by Total Assets
Key competitors of Oncologix Tech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
|
Cartesian Growth Corporation III Unit
NASDAQ:CGCTU
|
USA | $281.56 Million |
|
Azure Holding Group Corp
PINK:AZRH
|
USA | $16.92 Million |
|
Constellation Capital Corp.
V:CNST-P
|
Canada | CA$627.53K |
|
Little Fish Acquisition I Corp.
V:LILL-P
|
Canada | CA$56.48K |
|
Hana 30 Special Purpose Acquisition Company
KQ:469880
|
Korea | ₩17.89 Billion |
|
Chicane Capital I Corp.
V:CCIC-P
|
Canada | CA$199.07K |
|
Cuspis Capital II Ltd
V:CCII-P
|
Canada | CA$1.51 Million |
Oncologix Tech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Oncologix Tech Inc generates 1.91x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oncologix Tech Inc is currently not profitable relative to its asset base.
Oncologix Tech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.22 | 0.03 |
| Quick Ratio | 0.04 | 0.20 | 0.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.96 Million | $ -4.16 Million | $ -615.74K |
Oncologix Tech Inc - Advanced Valuation Insights
This section examines the relationship between Oncologix Tech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -30.6% |
| Total Assets | $1.50 Million |
| Market Capitalization | $73.66K USD |
Valuation Analysis
Below Book Valuation: The market values Oncologix Tech Inc's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oncologix Tech Inc's assets decreased by 30.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncologix Tech Inc (1996–2017)
The table below shows the annual total assets of Oncologix Tech Inc from 1996 to 2017.
| Year | Total Assets | Change |
|---|---|---|
| 2017-08-31 | $1.50 Million | -30.56% |
| 2016-08-31 | $2.15 Million | -31.27% |
| 2015-08-31 | $3.13 Million | +46.70% |
| 2014-08-31 | $2.14 Million | +5.00% |
| 2013-08-31 | $2.03 Million | +31654.10% |
| 2012-08-31 | $6.41K | -58.33% |
| 2011-08-31 | $15.37K | -17.33% |
| 2010-08-31 | $18.59K | -13.23% |
| 2009-08-31 | $21.43K | -91.08% |
| 2008-08-31 | $240.32K | -60.80% |
| 2007-08-31 | $613.08K | -8.35% |
| 2006-08-31 | $668.96K | +45.75% |
| 2005-08-31 | $458.97K | -50.31% |
| 2004-08-31 | $923.69K | -83.85% |
| 2003-08-31 | $5.72 Million | -39.80% |
| 2002-08-31 | $9.50 Million | -15.66% |
| 2001-08-31 | $11.26 Million | -18.74% |
| 2000-08-31 | $13.86 Million | +780.52% |
| 1999-08-31 | $1.57 Million | -38.07% |
| 1998-08-31 | $2.54 Million | -19.06% |
| 1997-08-31 | $3.14 Million | -31.43% |
| 1996-08-31 | $4.58 Million | -- |